Young-Joon Kang1, Se Jeong Oh1, Hoon Choi1, Shijin Cho1, Chang-Hyun Shin1, Chaiwon Kim2, Joohyun Woo3, JungSun Lee4, Heung Kyu Park5, Han-Byoel Lee6,7,8, Woo Chul Noh9, Yong-Seok Kim10. 1. Department of Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 271, Cheonbo-Ro, Uijeongbu-si, Gyeonggi-do, 11765, Republic of Korea. 3. Department of Surgery, Ewha Cancer Center for Women, Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea. 4. Department of Surgery, Inje University, College of Medicine, Haeundae-Paik Hospital, Busan, Republic of Korea. 5. Department of Surgery, Breast Cancer Center, Gachon University Gil Hospital, Incheon, Republic of Korea. 6. Department of Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea. 7. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 8. Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. 9. Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea. 10. Department of Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 271, Cheonbo-Ro, Uijeongbu-si, Gyeonggi-do, 11765, Republic of Korea. dydtjr97@catholic.ac.kr.
Abstract
PURPOSE: The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials. The objective of this study was to evaluate the survival of patients in a monoethnic group diagnosed with T1b lymph node-negative breast cancer depending on HER2 status. METHODS: We analyzed 3110 patients with T1bN0M0 breast cancer whose data were deposited into the Korean Breast Cancer Society Registry database between 2000 and 2009. Overall survival (OS) and breast cancer-specific survival (BCSS) were compared according to HER2 status. RESULTS: Among all patients, 494 (15.9%) had HER2-positive breast cancer. At a mean follow-up of 93 months, 108 deaths and 86 breast cancer-specific deaths were noted among all patients. There was no significant difference in OS between the HER2-negative and HER2-positive groups (p = 0.103). The same result was observed for BCSS. However, in the subgroup of estrogen receptor (ER)-positive women, HER2-negative patients had a better BCSS prognosis than HER2-positive patients (p = 0.025). Multivariate analysis also indicated a significant difference in BCSS in the ER-positive subgroup (HR 2.60; 95% CI 1.15-5.87; p = 0.021). CONCLUSION: This study analyzed a large nationwide and monoethnic cohort and found a significant difference only in BCSS in the ER-positive subgroup according to HER2 status. Anti-HER2 therapy may be considered in HER2-positive and ER-positive patients with small, node-negative breast cancer.
PURPOSE: The prognosis of patients with node-negative T1b tumors according to human epidermal growth factor receptor 2 (HER2) status is not known. This group of patients has not been studied in the available randomized trials. The objective of this study was to evaluate the survival of patients in a monoethnic group diagnosed with T1b lymph node-negative breast cancer depending on HER2 status. METHODS: We analyzed 3110 patients with T1bN0M0 breast cancer whose data were deposited into the Korean Breast Cancer Society Registry database between 2000 and 2009. Overall survival (OS) and breast cancer-specific survival (BCSS) were compared according to HER2 status. RESULTS: Among all patients, 494 (15.9%) had HER2-positive breast cancer. At a mean follow-up of 93 months, 108 deaths and 86 breast cancer-specific deaths were noted among all patients. There was no significant difference in OS between the HER2-negative and HER2-positive groups (p = 0.103). The same result was observed for BCSS. However, in the subgroup of estrogen receptor (ER)-positive women, HER2-negative patients had a better BCSS prognosis than HER2-positive patients (p = 0.025). Multivariate analysis also indicated a significant difference in BCSS in the ER-positive subgroup (HR 2.60; 95% CI 1.15-5.87; p = 0.021). CONCLUSION: This study analyzed a large nationwide and monoethnic cohort and found a significant difference only in BCSS in the ER-positive subgroup according to HER2 status. Anti-HER2 therapy may be considered in HER2-positive and ER-positive patients with small, node-negative breast cancer.
Entities:
Keywords:
Breast cancer; ERBB-2; Human epidermal growth factor receptor 2; Intrinsic factor; Trastuzumab
Authors: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Heikki Joensuu; Jorma Isola; Mikael Lundin; Tiina Salminen; Kaija Holli; Vesa Kataja; Liisa Pylkkänen; Taina Turpeenniemi-Hujanen; Karl von Smitten; Johan Lundin Journal: Clin Cancer Res Date: 2003-03 Impact factor: 12.531
Authors: Ines Vaz-Luis; Rebecca A Ottesen; Melissa E Hughes; Rizvan Mamet; Harold J Burstein; Stephen B Edge; Ana M Gonzalez-Angulo; Beverly Moy; Hope S Rugo; Richard L Theriault; Jane C Weeks; Eric P Winer; Nancy U Lin Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Louis Fehrenbacher; Angela M Capra; Charles P Quesenberry; Regan Fulton; Parveen Shiraz; Laurel A Habel Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Stephen Chia; Brian Norris; Caroline Speers; Maggie Cheang; Blake Gilks; Allen M Gown; David Huntsman; Ivo A Olivotto; Torsten O Nielsen; Karen Gelmon Journal: J Clin Oncol Date: 2008-11-10 Impact factor: 44.544
Authors: Cornelia Kolberg-Liedtke; Diana Lüftner; Sara Y Brucker; Wilfried Budach; Carsten Denkert; Peter A Fasching; Renate Haidinger; Nadia Harbeck; Jens Huober; Christian Jackisch; Wolfgang Janni; David Krug; Thorsten Kühn; Sibylle Loibl; Volkmar Müller; Andreas Schneeweiss; Christoph Thomssen; Michael Untch; Marc Thill Journal: Breast Care (Basel) Date: 2022-04-08 Impact factor: 2.268